An interventional study of G2 and G3 in Glaucoma, Open-Angle, sponsored by Glaukos Corporation. Terminated at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-09-09.
Sponsored by Glaukos Corporation · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Glaucoma, Open-Angle by Glaukos Corporation — 7 open to participants now, 10 under way, 2 of them phase 3. Glaucoma, Open-Angle · Glaukos Corporation.
Among the 43 studies in Glaucoma, Open-Angle by Glaukos Corporation, this one is the 37th largest by enrollment of the 38 interventional ones that give a count, is the only one that started in 2017, is one of 15 with no phase, and was the 26th registered.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.
Browse Glaucoma, Open-Angle studies →7 of the 43 studies in Glaucoma, Open-Angle by Glaukos Corporation are open now, in 1 country. Recruiting first, the newest first:
Glaukos Corporation · Sites in United States
Ages 18+
Glaukos Corporation · Sites in United States
Ages 18+
Glaukos Corporation · Sites in United States
Ages 18+
Glaukos Corporation · Sites in United States
Ages 18+
Glaukos Corporation · Sites in United States
Ages 45+
By country, each count listing its studies:
Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 7 is below the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.
Median enrollment 111 across the 38 interventional studies, 108 across the 5 observational. Of the 30 that completed or were terminated, 8 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
Glaukos Corporation is the lead sponsor of 67 studies on the registry; 14 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 7 (54%) have results posted.
2 of the studies in Glaucoma, Open-Angle by Glaukos Corporation that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07816692Glaukos CorporationiDose TR Administration in an Office-Based Surgery Setting | 2027-03 |
| NCT06066645Glaukos CorporationTravoprost Intraocular Implant + iStent Infinite | 2027-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 43 studies in Glaucoma, Open-Angle by Glaukos Corporation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Prospective Evaluation of Open-Angle Glaucoma Subjects treated with two second generation iStents and one iStent Supra
Prospective Evaluation of Mild to Moderate Open-Angle Glaucoma Subjects treated with Two Second Generation Microbypass Stents and One Suprachoroidal Stent
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Two iStent inject stents and one iStent Supra stent
Device: G2 and G3
Two iStent inject devices and one iStent supra device
20% IOP reduction
IOP reduction observed compared to baseline IOP, measured by Goldmann tonometry in mm Hg
Time frame: Month 12
IOP less than or equal to 18 mm Hg
IOP compared to baseline IOP, measured by Goldmann tonometry in mm Hg
Time frame: Month 12
Plan to share: No
No publications or documents are linked to this record.
Ran from Aug 2017 to primary completion in Jun 2019, 22 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.